Skip to content

Vera Therapeutics

US · VERA #2739 by market cap Listed 2021
25.45 -1.30 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/11/13
  • Company notice
    Vera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Oliger Christy J.
    SEC · 2026/5/27
  • Rating change
    Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/15
  • Company notice
    Takeda Pharmaceutical: The U.S. FDA has accepted Rusfertide's New Drug Application and designated it for Priority Review, with the potential to become a first-in-class treatment for polycythemia vera.
    JPX · 2026/3/2
  • Rating change
    A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $90
    Market Newswire · 2026/9/16
  • Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $66
    Market Newswire · 2026/11/6
  • Rating change
    BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $60
    Market Newswire · 2026/10/9
  • BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating
    Market Newswire · 2026/11/7
  • Rating change
    H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $75
    Market Newswire · 2026/11/6
  • Rating change
    Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.
    Dow Jones · 2026/11/6
  • Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/11/6
  • Rating change
    Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34
    Market Newswire · 2026/10/24
  • Rating change
    Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $76
    Market Newswire · 2026/10/23
  • Rating change
    H.C. Wainwright Remains a Buy on Vera Therapeutics (VERA)
    TipRanks · 2026/10/1
  • Nebius announced it has begun deploying NVIDIA Vera Rubin systems and expressed optimism regarding the growing demand for high-performance CPUs.
    Latest · 2026/11/12
  • Rating change
    H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/10/1
  • Rating change
    TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/8/31
  • Company notice
    Takeda Pharmaceutical: Regarding the U.S. Food and Drug Administration (FDA) approval of MIMRYLO (rusfertide), which has the potential to usher in a paradigm shift in the treatment of polycythemia vera.
    JPX · 2026/8/29
  • Company notice
    Takeda Pharmaceutical: Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
    JPX · 2026/8/29
  • Company notice
    Takeda Pharmaceutical: Takeda Announces U.S. FDA Accepts NDA and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
    JPX · 2026/3/2
  • Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/24
  • Rating change
    HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
    Benzinga · 2026/8/12
  • The value per Vera Rubin NVL72 rack has nearly doubled, which is expected to boost Lenovo Group's ISG operating margin by nearly 1 percentage point.
    Gelonghui Finance · 2026/10/30
  • Rating change
    J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76
    Market Newswire · 2026/8/17
  • Rating change
    A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $100
    Market Newswire · 2026/8/11

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vera Therapeutics discussion 0 comments

Add a comment